Zusammenfassung
Hauptvertreter der Hypophysen- und Hypothalamushormone sind Wachstumshormon, Somatostatin, Gonadotropinpräparate und Vasopressinanaloga. Wachstumshormonpräparate haben ihre bisherige Aufwärtsentwicklung nicht weiter fortgesetzt, sind aber mit Kosten von 190 Mio. € weiterhin die umsatzstärkste Gruppe der Hypophysen-und Hypothalamushormone. Leichte Zunahmen zeigen Somatostatinanaloga (86 Mio. €) und Follitropinpräparate (48 Mio. €). Die Verordnungskosten der Vasopressinanaloga für die Behandlung des zentralen Diabetes insipidus waren annähernd konstant (17 Mio. €).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Literatur
Al-Inany HG, Abou-Setta AM, Aboulghar M (2006): Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev. 2006 Jul 19; 3: CD00175–0
Andrejak M, Tribouilloy C (2013): Drug-induced valvular heart disease: an update. Arch Cardiovasc Dis 106: 333–339
de Mouzon J, Allavena E, Schmitt C, Frappe M (2004): In vitro fertilization in France: economic aspects and influence of the gonadotropin choice (urinary vs. recombinant) on cost. Gynecol Obstet Fertil 32: 508–518. [Article in French]
Fleseriu M (2011): Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review. Pituitary 14: 184–193
International Recombinant Human Chorionic Gonadotropin Study Group (2001): Induction of ovulation in World Health Organization group II anovulatory women undergoing follicular stimulation with recombinant human follicle-stimulating hormone: a comparison of recombinant human chorionic gonadotropin (rhCG) and urinary hCG. Fertil Steril 75: 1111–1118
Liu H, Bravata DM, Olkin I, Nayak S, Roberts B, Garber AM, Hoffman AR (2007): Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 146: 104–115
Löndahl M, Nilsson A, Lindgren H, Katzman P (2008): A case of constrictive pericarditis during cabergoline treatment for hyperprolactinaemia. Eur J Endocrinol 158: 583–585
Melmed S (2006): Acromegaly. N Engl J Med 355: 2558–2573
National Institute for Clinical Excellence (NICE) (2002): Guidance on the use of human growth hormone (somatropin) in children with growth failure. Technology Appraisal No. 42. Internet: www.nice.org.uk/page.aspx?o= TA042guidance
National Institute for Health and Clinical Excellence (NICE) (2003): Human growth hormone (somatropin) in adults with growth hormone deficiency. Technology Appraisal 64. Internet: www.nice.org.uk/page.aspx?o=TA064guidance
Pacchiarotti A, Sbracia M, Frega A, Selman H, Rinaldi L, Pacchiarotti A (2010): Urinary hMG (Meropur) versus recombinant FSH plus recombinant LH (Pergoveris) in IVF: a multicenter, prospective, randomized controlled trial. Fertil Steril 94: 2467–2469
Perales-Puchalt A, Legro RS (2013): Ovulation induction in women with polycystic ovary syndrome. Steroids 78: 767–772
Savage MO, Drake WM, Carroll PV, Monson JP (2004): Transitional care of GH deficiency: when to stop GH therapy. Eur J Endocrinol 151 Suppl 1: S61–65
Striegel H, Simon P (2007): Doping: High-Tech-Betrug im Sport. Internist: 48: 737–742
van der Lely AJ, Biller BM, Brue T, Buchfelder M, Ghigo E, Gomez R, Hey-Hadavi J, Lundgren F, Rajicic N, Strasburger CJ, Webb SM, Koltowska-Häggström M (2013): Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab 97: 1589–1597
van Wely M, Kwan I, Burt AL, Thomas J, Vail A, Van der Veen F, Al-Inany HG (2011): Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database Syst Rev. 2011 Feb 16; 2: CD00535–4
van Wely M, Kwan I, Burt AL, Thomas J, Vail A, Van der Veen F, Al-Inany HG (2012): Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. A Cochrane review. Hum Reprod Update 18: 11–1
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Schwabe, U. (2014). Hypophysen- und Hypothalamushormone. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs- Report 2014. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-43487-1_28
Download citation
DOI: https://doi.org/10.1007/978-3-662-43487-1_28
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-43486-4
Online ISBN: 978-3-662-43487-1
eBook Packages: Medicine (German Language)